Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 3/20 | 0.50 |
| ▸ | CTSK | P43235 | 3/20 | 0.50 |
| ▸ | ACE | P12821 | 2/20 | 0.49 |
| ▸ | CCKAR | P32238 | 3/20 | 0.49 |
| ▸ | CCKBR | P32239 | 3/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401320 | 1.00 | ADAM17 (0.58) | ADAM17L3MBTL1CTSSCTSKACE | |
| SCHEMBL4294679 | 1.00 | ADAM17 (0.58) | ADAM17L3MBTL1CTSSCTSKACE | |
| SCHEMBL22804050 | 1.00 | ADAM17 (0.58) | ADAM17L3MBTL1CTSSCTSKACE | |
| SCHEMBL29400491 | 1.00 | ADAM17 (0.58) | ADAM17L3MBTL1CTSSCTSKACE | |
| SCHEMBL29401255 | 0.91 | ADAM17 (0.58) | ADAM17L3MBTL1CTSSCTSKCCKAR | |
| SCHEMBL18002447 | 0.91 | CTSS (0.50) | ADAM17L3MBTL1CTSSCTSKACE | |
| SCHEMBL29401597 | 0.91 | ADAM17 (0.58) | ADAM17L3MBTL1CTSSCTSKCCKAR | |
| SCHEMBL21309886 | 0.90 | L3MBTL1 (0.57) | ADAM17L3MBTL1CTSSCTSKCCKAR | |
| SCHEMBL29169598 | 0.90 | L3MBTL1 (0.57) | ADAM17L3MBTL1CTSSCTSKCCKAR | |
| SCHEMBL22804106 | 0.90 | ADAM17 (0.53) | ADAM17L3MBTL1ACECCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | claimed |
| CN-112480122-B | Tetrahydroimidazo [1,2-a ] pyrazine compound, composition, preparation method and application thereof | 中山大学 | 2022-03-22 | — | — | CN | claimed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| EP-3988538-B1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO LTD (CN) | 2024-08-07 | — | — | EP | disclosed |
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | disclosed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
| US-20220111056-A1 | DRUG-LOADED EMULSION | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
| US-20220110909-A1 | PREPARATION METHOD AND USE OF MODIFIED HYDROPHOBIC EXCIPIENT | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
| CN-112480122-B | Tetrahydroimidazo [1,2-a ] pyrazine compound, composition, preparation method and application thereof | 中山大学 | 2022-03-22 | — | — | CN | disclosed |
| CN-112480122-A | Tetrahydroimidazo [1,2-a ] pyrazine compound, composition, preparation method and application thereof | 中山大学 | 2021-03-12 | — | — | CN | disclosed |
| US-8513187-B2 | Soft protease inhibitors, and pro-soft forms thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120178677-A1 | SOFT PROTEASE INHIBITORS, AND PRO-SOFT FORMS THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2012-07-12 | — | — | US | disclosed |
| US-7893042-B2 | Boc-glycyl-phenazopyridine; phenazopyridines covalently attached to various conjugates; useful for providing increased (oral) bioavailability with reduced side effects | PINNACLE PHARMACEUTICALS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100204185-A1 | PHENAZOPYRIDINE COMPOUNDS | PINNACLE PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | CETP, LIPA, MTTP | ADAM17 2068/4885L3MBTL1 3657/4885CTSS 2330/4885 |
| US-20100204185-A1 | PHENAZOPYRIDINE COMPOUNDS | CYP3A5, CYP3A4, CYP2D6 | ADAM17 4275/4885L3MBTL1 4799/4885CTSS 2668/4885 |
| US-20120178677-A1 | SOFT PROTEASE INHIBITORS, AND PRO-SOFT FORMS THEREOF | DPP4, LIPE, PREP | ADAM17 41/4885L3MBTL1 556/4885CTSS 111/4885 |
| US-20220111056-A1 | DRUG-LOADED EMULSION | SLC43A1, SLC7A1, CETP | ADAM17 3404/4885L3MBTL1 799/4885CTSS 3871/4885 |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | CETP, SLC43A1, SLC27A1 | ADAM17 2880/4885L3MBTL1 554/4885CTSS 3839/4885 |
| US-20220110909-A1 | PREPARATION METHOD AND USE OF MODIFIED HYDROPHOBIC EXCIPIENT | ABCG2, CYP51A1, HACD3 | ADAM17 1796/4885L3MBTL1 3778/4885CTSS 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.